| Arcutis Biotherapeutics Inc (ARQT) | |||
|---|---|---|---|
| 9.1 -0.35 (-3.7%) | 04-19 16:00 | ||
| Open: | 9.36 | Pre. Close: | 9.45 |
| High: | 9.455 | Low: | 8.435 |
| Volume: | 4,519,442 | Market Cap: | 1,046(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |  |
| Target: | Six months: 13.27  One year: 15.38 |
| Support: | Support1: 8.44 Support2: 7.02 |
| Resistance: | Resistance1: 11.36 Resistance2: 13.17 |
| Pivot: | 10.62 |
| Moving Averages: | MA(5): 9.80 MA(20): 10.34 MA(100): 6.72  MA(250): 7.32 |
| MACD: | MACD(12,26): 0.05 Signal(12,26,9): 0.32 |
| %K %D: | %K(14,3): 16.15 %D(3): 20.41 |
| RSI: | RSI(14): 40.84 |
| 52-Week: | High: 15.21 Low: 1.76 Change(%): -34.1 |
| Average Vol(K): | 3-Month: 4560 10-Days: 3258 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 9.454 - 9.518 | 9.518 - 9.57 |
| Low: | 8.329 - 8.385 | 8.385 - 8.432 |
| Close: | 9.011 - 9.11 | 9.11 - 9.191 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ARQT ] has closed above bottom band by 17.3%. Bollinger Bands are 73.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue. |
| Company profile |
|---|
| Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Underperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: NASDAQ Global Select | |
| Sector: Healthcare | |
| Industry: Biotechnology | |
| Shares Out. (M) | 114.97 |
| Shares Float (M) | 74.79 |
| % Held by Insiders | 2.40 |
| % Held by Institutions | 95.86 |
| Shares Short (K) | 19260 |
| Shares Short Prior Month (K) | 15780 |
| Stock Financials | |
|---|---|
| EPS | -3.780 |
| Book Value (p.s.) | 0.920 |
| Profit Margin | |
| Operating Margin | -452.23 |
| Return on Assets (ttm) | -38.1 |
| Return on Equity (ttm) | -175.8 |
| Qtrly Rev. Growth | 356.8 |
| Gross Profit (p.s.) | |
| Sales Per Share | 0.518 |
| EBITDA (p.s.) | -2.084 |
| Qtrly Earnings Growth | |
| Operating Cash Flow (M) | -247.06 |
| Levered Free Cash Flow (M) | -151.32 |
| Stock Valuation | |
|---|---|
| PE Ratio | -2.41 |
| PEG Ratio | -0.48 |
| Price to Book value | 9.89 |
| Price to Sales | 17.55 |
| Price to Cash Flow | -4.23 |
| Stock Dividends | |
|---|---|
| Dividend | |
| Dividend Yield | |
| Dividend Growth | |
